[Randomized Study Comparing the Exploratory Treatment For Gemtuzumab ozogamicin / Cytarabine to Standard Treatment For Idarubicin / Cytarabinechez The Elderly 65 to 80 Years and having acute myeloid leukemia with favourable or intermediate-risk cytogenetics] .

Trial Profile

[Randomized Study Comparing the Exploratory Treatment For Gemtuzumab ozogamicin / Cytarabine to Standard Treatment For Idarubicin / Cytarabinechez The Elderly 65 to 80 Years and having acute myeloid leukemia with favourable or intermediate-risk cytogenetics] .

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms ALFA1401
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Feb 2016 Planned End Date changed from 1 Apr 2020 to 1 Nov 2020 as reported by ClinicalTrials.gov.
    • 24 Feb 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top